Total current assets Total assets Related and Nonrelated Parties [Axis] Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balances Balances Total liabilities and stockholders’ equity Statement of Income Location, Balance [Axis] Total operating expenses Total operating expenses Loss from operations Loss from operations Total other income, net Net loss Net loss Comprehensive Income (Loss), Net [Abstract] Total comprehensive loss Balances (in Shares) Balances (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Nature of the Business and Basis of Presentation [Abstract] Summary of Significant Accounting Policies [Abstract] Reverse Recapitalization and Pre-Closing Financing [Abstract] Schedule of the Assets and Liabilities [Abstract] Net assets acquired PIPE Financings [Abstract] ATM Offering [Abstract] Fair Value Measurements [Abstract] Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Cash Equivalents and Marketable Securities [Abstract] Marketable securities Financial Instrument [Axis] Cash and Cash Equivalents [Axis] Marketable Securities [Axis] Total Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Accrued Expenses and Other Current Liabilities [Abstract] Total Accrued expenses and other current liabilities Note Payable with Related Party [Abstract] Convertible Preferred Stock and Stockholders’ Equity [Abstract] Schedule of Preferred Stock [Abstract] Schedule of Common Stock Reserved for Future Issuance [Abstract] Class of Warrant or Right [Axis] Plan Name [Axis] Stock-Based Compensation [Abstract] Schedule of Stock Option Activity [Abstract] Number of Stock Options Outstanding Outstanding options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Beginning balance Ending balance Number of warrants issued Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Grant Date Fair Value, Ending Balance Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Grant Date Fair Value, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Segment Disclosures [Abstract] Income Taxes [Abstract] Schedule of Loss Before Income Tax Expense [Abstract] Loss before income tax expense Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract] Income tax (benefit) expense Provision for income taxes Income tax (benefit) expense Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract] Total deferred tax assets Total deferred tax liabilities Deferred tax assets, net Schedule of Net Deferred Tax Assets [Abstract] Beginning balance Ending balance Valuation allowance Schedule of Unrecognized Tax Benefits [Abstract] Beginning balance Ending balance Option Agreements and License Agreements [Abstract] Commitments and Contingencies [Abstract] Schedule of Company’s Supplemental Cash Flow Information Related to Leases [Abstract] Schedule of Company’s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract] Total undiscounted lease payments Total discounted lease payments Net Loss per Share [Abstract] Antidilutive Securities [Axis] Related Party Transactions [Abstract] 401(k) Plan [Abstract] Director [Member] Assets Current assets: Cash and cash equivalents Marketable securities, current Due in one year or less Prepaid expenses and other current assets Marketable securities, long-term Due in 1-2 years Property and equipment, net Operating lease right-of-use assets Other non-current assets Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Operating lease liability, current Less: current portion of lease liability Related party accounts payable and other current liabilities Accounts payable and other current liabilities Operating lease liability, non-current Non-current portion of lease liability Commitments and contingencies (Note 15) Stockholders’ equity: Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of December 31, 2025 and 2024; 137,138 shares issued and outstanding as of December 31, 2025 and 2024 Carrying Value (in Dollars) Non-voting convertible preferred stock, par value (in Dollars per share) Preferred stock par value per share (in Dollars per share) Non-voting convertible preferred stock, shares authorized (in Shares) Preferred Stock Authorized Non-voting convertible preferred stock, shares issued (in Shares) Preferred Stock Issued Non-voting convertible preferred stock, shares outstanding (in Shares) Preferred Stock Outstanding Preferred stock, shares outstanding Common stock, $0.001 par value as of December 31, 2025 and 2024; 545,000,000 shares authorized as of December 31, 2025 and 2024, 48,722,309 and 37,440,510 shares issued and outstanding as of December 31, 2025 and 2024, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares authorized Common stock, shares issued (in Shares) Common stock, shares issued Common stock, shares outstanding (in Shares) Common stock, shares outstanding Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated deficit Operating expenses: Research and development Related party amount General and administrative Other income (expense): Interest income Other income (expense), net Net loss per share attributable to stockholders, basic (in Dollars per share) Loss Per Share, Basic Net loss per share attributable to stockholders, Diluted (in Dollars per share) Loss Per Share, Diluted Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) Weighted Average Shares Outstanding, Basic Weighted-average shares used in computing Net loss per share attributable to stockholders, diluted (in Shares) Weighted Average Shares Outstanding, Diluted Other comprehensive income (loss): Unrealized gains (losses) on marketable securities Issuance of common stock Issuance of common stock (in Shares) Issuance of Series A convertible preferred stock, net of issuance costs of $69 Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) Issuance costs Net of issuance costs (in Dollars) Issuance costs (in Dollars) Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares) Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares) Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares) Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing (in Shares) Issuance costs of 2024 PIPE Financing Conversion of Series A non-voting convertible preferred stock to common stock Conversion of Series A non-voting convertible preferred stock to common stock (in Shares) Issuance of common stock under employee stock purchase plan Issuance of common stock under employee stock purchase plan (in Shares) Stock issued during period, shares, employee stock purchase plans Reclassification of the Paruka warrant from liability to equity Stock-based compensation expense Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing (in Shares) Issuance cost of the 2025 PIPE Financing Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of pre-funded warrants (in Shares) Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock upon exercise of stock options and employee warrants (in Shares) Cancellation of restricted stock awards Cancellation of restricted stock awards (in Shares) Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Non-cash interest expense Non-cash lease expense Depreciation expense Changes in operating assets and liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liability Related party accounts payable and other current liabilities Cash flows from investing activities: Proceeds from maturities of marketable securities Cash flows from financing activities: Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid Gross proceeds (in Dollars) Proceeds from issuance of notes payable to related party, net of issuance costs paid Proceeds from the Pre-Closing Financing, net Proceeds from the PIPE Financings, net Cash acquired in connection with the reverse recapitalization Proceeds from issuance of common stock upon exercise of stock options and employee warrants and purchases under employee stock purchase plan